Austin J Pathol Lab Med. 2014;1(1): 1.
Molnar C1, Neagoe VI1*, Butiurca VO1, Tataru S1, Stolnicu S2 and Molnar CV3
1Departament of General Surgery I, University of Medicine and Pharmacy Targu Mures, Romania
2Departament of Phatology, University of Medicine and Pharmacy Targu Mures, Romania
3Departament of Obstetrics and Ginecology I, University of MedicineandPharmacyTarguMures, Romania
*Corresponding author: Neagoe VI, Departament of General Surgery I, University of Medicine and Pharmacy Targu Mures, Romania, 50 Gheorghe Marinescu St, Targu Mures, Romania
Received: August 08, 2014; Accepted: August 11, 2014; Published: August 13, 2014
In theera of constantly changing treatment guidelines for breast cancer, neo adjuvant chemotherapy has been widely accepted and a complete pathological response after this type of breast cancer management is associated with better outcomes. Good quality core biopsy specimens and the evidence of estrogen receptors, progesterone receptors and HER2 status are vital for a good neo adjuvant therapeutic approach. In selected cases, patients with breast tumors larger than 2cm can be treated also by neo adjuvant endocrine therapy. We use preoperative chemotherapy approach with the aim of downgrading of high-risk breast cancers (tumors>2cm and locally advanced, which are ineligible for resection). As a particularity we present preoperative images (Figure 1 and 2) from two cases of no response to neo adjuvant chemotherapy following the NCCN guidelines for breast cancer stage III and IV. In both cases we have performed modified radical mastectomy and radical auxiliary lymph node dissection (Madden procedure) with good outcomes.
Figure 1:Blue circle describing left breast tumor and black circle left axillary lymphadenophaty.
Citation: Molnar C, Neagoe VI, Butiurca VO, Tataru S, Stolnicu S and Molnar CV. No Response to Primary Neo Adjuvant Chemotherapy in Two Cases of Stage III and IV Breast Cancer. Austin J Pathol Lab Med. 2014;1(1): 1. ISSN:2471-0156